Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 11, 2010, Pages 3314-3321

  Wang, Haishan ^a   Lim, Ze Yi ^a   Zhou, Yan ^a   Ng, Melvin ^a   Lu, Ting ^a   Lee, Ken ^a   Sangthongpitag, Kanda ^a   Goh, Kee Chuan ^a   Wang, Xukun ^a   Wu, Xiaofeng ^a   Khng, Hwee Hoon ^a   Goh, Siok Kun ^a   Ong, Wai Chung ^a   Bonday, Zahid ^a   Sun, Eric T ^a  

^a S BIO Pte Ltd   (Singapore)

Author keywords

Acylurea; Anticancer; Efficacy; HDAC inhibitor; Hydroxamic acid; SAR

Indexed keywords

ACYLUREA; BELINOSTAT; BENZOYLISOCYANATE; CYANIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; PANOBINOSTAT; SB 207; SULFONYLUREA; UNCLASSIFIED DRUG; UREA DERIVATIVE; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PROSTATE CANCER; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE, TUMOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KINETICS; MICE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; UREA;

EID: 77953478662     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.041     Document Type: Article

References (30)

1. De Ruijter A.J.M., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B.P. Biochem. J. 370 (2003) 737
2. Michan S., and Sinclair D. Biochem. J. 404 (2007) 1
3. Curtin M., and Glaser K. Curr. Med. Chem. 10 (2003) 2373
4. Glaser K.B., Li J., Staver M.J., Wei R.-Q., Albert D.H., and Davidsen S.K. Biochem. Biophys. Res. Commun. 310 (2003) 529
5. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., and Richon V.M. Cancer Res. 60 (2000) 5165
6. FDA approval and New Drug Application (NDA) documents for Zolinza™ (SAHA, vorinostat): http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021991s000_Zolinz aTOC.cfm.
7. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., and Nakanishi O. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4592
8. Suzuki T., Ando T., Tsuchiya K., Fukasawa N., Saito A., Mariko Y., Yamashita T., and Nakanishi O. J. Med. Chem. 42 (1999) 3001
9. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Thangue N.B., and Brown R. Mol. Cancer Ther. 2 (2003) 721
10. For review of chemical types and SAR of HDAC inhibitors, see:. Paris M., Porcelloni M., Binaschi M., and Fattori D. J. Med. Chem. 51 (2008) 1505
11. Miller T.A., Witter D.J., and Belvedere S. J. Med. Chem. 46 (2003) 5097
12. Xie A., Liao C., Li Z., Ning Z., Hu W., Lu X., Shi L., and Zhou J. Curr. Med. Chem. - Anti Cancer Agents 4 (2004) 273
13. Lim, Z.-Y.; Wang, H.; Zhou, Y. WO 2005040101A1, 2005.
14. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Nature 401 (1999) 188
15. Wang D.-F., Helquist P., Wiech N.L., and Wiest O. J. Med. Chem. 48 (2005) 6936
16. Barlaam B., Hamon A., and Maudet M. Tetrahedron Lett. 39 (1998) 7865
17. Hill A.J., and Degnan W.M. J. Am. Chem. Soc. 62 (1940) 1595
18. Caubere, P.; Den, M.-Z.; Lecolier, S.; Senet, J. P. Eur. Pat. Appl. EP 334720 B1, 1992.
19. Wang H., Yu N., Song H., Chen D., Zou Y., Deng W., Lye P.L., Chang J., Ng M., Blanchard S., Sun E.T., Sangthongpitag K., Wang X., Goh K.C., Wu X., Khng H.H., Fang L., Goh S.K., Ong W.C., Bonday Z., Stunkel W., Poulsen A., and Entzeroth M. Bioorg. Med. Chem. Lett. 19 (2009) 1403
20. m)). Anti-proliferations assays: similar protocols used as published in Ref. 14.
21. Remiszewski S.W., Sambucetti L.C., Atadja P., Bair K.W., Cornell W.D., Green M.A., Howell K.L., Jung M., Kwon P., Trogani N., and Walker H. J. Med. Chem. 45 (2002) 753
22. Jung M., Brosch G., Kölle D., Scherf H., Gerhäuser C., and Loid P. J. Med. Chem. 42 (1999) 4669
23. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., and Sehested M. Biochem. J. 409 (2008) 581
24. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., and Schreiber S.L. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4389
25. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., Chakravarty P., Paolini C., De Francesco R., Gallinari P., Steinkühler C., and Di Marco S. Proc. Natl. Acad. Sci. U.S.A. 19 (2004) 15064
26. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., and Richon V.M. J. Clin. Oncol. 23 (2005) 3923
27. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 10014
28. Gui C.Y., Ngo L., Xu W.S., Richon V.M., and Marks P.A. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1241
29. Yeo P., Liu X., Goh E., New L.S., Zeng P., Wu X., Venkatesh P., and Kantharaj E. Biomed. Chromatogr. 21 (2007) 184
30. Xenograft studies. Similar protocols used as published in Ref. 14. Compounds were dissolved in 10% N,N-dimethylacetamide (DMA)/10% Cremophore/80% water for ip route or 0.5% methylcellulose/0.1%Tween 80 (MC/TW) for oral administration. Statistic analysis was done with one-way ANOVA followed by Dunnett's Multiple Comparison test (Prism 4.0).